80 related articles for article (PubMed ID: 26800468)
1. [Management of treatment in patients with neuroendocrine neoplasmas of digestive tract].
Kiňová S; Kováčová M; Čaprnda M; Koreň M
Vnitr Lek; 2015; 61 Suppl 5():12-20. PubMed ID: 26800468
[TBL] [Abstract][Full Text] [Related]
2. [Management of treatment in patients with neuroendocrine neoplasmas of digestive tract].
Kinová S; Kovácová M; Caprnda M; Koren M
Vnitr Lek; 2015 Dec; 61(12 Suppl 5):5S12-20. PubMed ID: 27124967
[TBL] [Abstract][Full Text] [Related]
3. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors.
Stokkel MP; Rietbergen DD; Korse CM; Taal BG
Nucl Med Commun; 2011 Aug; 32(8):731-7. PubMed ID: 21633314
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
7. Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker.
Tohmola N; Itkonen O; Sane T; Markkanen H; Joenväärä S; Renkonen R; Hämäläinen E
Clin Chim Acta; 2014 Jan; 428():38-43. PubMed ID: 24211728
[TBL] [Abstract][Full Text] [Related]
8. [Basic and translational research progress of gastrointestinal neuroendocrine neoplasmas].
Song Y; Li X; Song T; Lin G; Chen Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1217-1221. PubMed ID: 27928788
[TBL] [Abstract][Full Text] [Related]
9. Biochemical diagnosis of neuroendocrine GEP tumor.
Oberg K
Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
[TBL] [Abstract][Full Text] [Related]
10. A jejunal stromal tumour in a patient with metastatic neuroendocrine cancer of unknown origin; a rare coexistence, diagnostic and therapeutic challenge.
El Ali Z; Iwanik K; Sowiński J; Swora E; Grzymislawski M
Endokrynol Pol; 2009; 60(3):216-20. PubMed ID: 19569023
[TBL] [Abstract][Full Text] [Related]
11. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
[TBL] [Abstract][Full Text] [Related]
12. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
[TBL] [Abstract][Full Text] [Related]
13. Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours.
Zandee WT; van Adrichem RC; Kamp K; Feelders RA; van Velthuysen MF; de Herder WW
Clin Endocrinol (Oxf); 2017 Aug; 87(2):165-170. PubMed ID: 28464233
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
15. [Surgical management of locally advanced digestive tract neuroendocrine neoplasm with or without liver metastasis].
Wang X; Qiu J; Wu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1222-1225. PubMed ID: 27928789
[TBL] [Abstract][Full Text] [Related]
16. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
[TBL] [Abstract][Full Text] [Related]
17. Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors.
Landry CS; Cavaness K; Celinski S; Preskitt J
Gland Surg; 2014 Nov; 3(4):215-8. PubMed ID: 25493250
[TBL] [Abstract][Full Text] [Related]
18. [Digestive neuroendocrine tumors].
de Mestier L; Deguelte-Lardière S; Brixi H; Kianmanesh R; Cadiot G
Rev Med Interne; 2016 Aug; 37(8):551-60. PubMed ID: 26897113
[TBL] [Abstract][Full Text] [Related]
19. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
Shia J; Tang LH; Weiser MR; Brenner B; Adsay NV; Stelow EB; Saltz LB; Qin J; Landmann R; Leonard GD; Dhall D; Temple L; Guillem JG; Paty PB; Kelsen D; Wong WD; Klimstra DS
Am J Surg Pathol; 2008 May; 32(5):719-31. PubMed ID: 18360283
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids.
Manfé AZ; Norberto L; Marchesini M; Lumachi F
In Vivo; 2011; 25(6):1027-9. PubMed ID: 22021701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
